Axsome Therapeutics, Inc. (AXSM)
137.01
-4.68
(-3.30%)
USD |
NASDAQ |
Nov 16, 16:00
135.01
-2.00
(-1.46%)
After-Hours: 06:47
Axsome Therapeutics Enterprise Value : 7.114B for Nov. 16, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 16, 2026 | 7.114B |
| November 13, 2026 | 7.360B |
| November 12, 2026 | 7.501B |
| November 11, 2026 | 7.757B |
| November 10, 2026 | 7.322B |
| November 09, 2026 | 6.954B |
| November 06, 2026 | 6.870B |
| November 05, 2026 | 6.735B |
| November 04, 2026 | 7.113B |
| November 03, 2026 | 7.251B |
| November 02, 2026 | 7.061B |
| October 30, 2026 | 7.504B |
| October 29, 2026 | 7.453B |
| October 28, 2026 | 7.456B |
| October 27, 2026 | 7.387B |
| October 26, 2026 | 7.485B |
| October 23, 2026 | 7.536B |
| October 22, 2026 | 8.116B |
| October 21, 2026 | 8.129B |
| October 20, 2026 | 8.301B |
| October 19, 2026 | 8.102B |
| October 16, 2026 | 8.172B |
| October 15, 2026 | 8.417B |
| October 14, 2026 | 8.439B |
| October 13, 2026 | 8.129B |
| Date | Value |
|---|---|
| October 12, 2026 | 8.638B |
| October 09, 2026 | 8.762B |
| October 08, 2026 | 8.853B |
| October 07, 2026 | 9.005B |
| October 06, 2026 | 9.077B |
| October 05, 2026 | 9.221B |
| October 02, 2026 | 9.335B |
| October 01, 2026 | 9.483B |
| September 30, 2026 | 9.605B |
| September 29, 2026 | 9.640B |
| September 28, 2026 | 10.05B |
| September 25, 2026 | 10.11B |
| September 24, 2026 | 10.16B |
| September 23, 2026 | 10.02B |
| September 22, 2026 | 10.53B |
| September 21, 2026 | 10.65B |
| September 18, 2026 | 10.77B |
| September 17, 2026 | 11.11B |
| September 16, 2026 | 10.99B |
| September 15, 2026 | 10.58B |
| September 14, 2026 | 11.23B |
| September 11, 2026 | 11.45B |
| September 10, 2026 | 10.95B |
| September 09, 2026 | 10.92B |
| September 08, 2026 | 10.77B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Eli Lilly & Co. | 1.392T |
| Filana Therapeutics, Inc. | -54.71M |
| CorMedix, Inc. | 172.70M |
| Eloxx Pharmaceuticals, Inc. | -4.166M |
| Breakthrough Chemistry, Inc. | 0.0854M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -12.88M |
| Revenue (Quarterly) | 259.69M |
| Total Expenses (Quarterly) | 272.57M |
| EPS Diluted (Quarterly) | -0.2455 |
| Gross Profit Margin (Quarterly) | 91.97% |
| Profit Margin (Quarterly) | -4.96% |
| Earnings Yield | -2.23% |
| Normalized Earnings Yield | -2.358 |